Sentences with phrase «as early clinical»

Such claims could lead to confusion for consumers as early clinical and epidemiological studies report conflicting or confusing results.

Not exact matches

Early clinical trials indicate that restricting calorie intake seems to trigger similarly promising physical changes in people, which is why it's sometimes discussed as a potential anti-aging intervention.

It is curious that the early days of clinical pastoral education, which has done more than any other movement to foster the present knowledge and skill in pastoral care, actually relied only in part upon interviewing methods and yet made the interview image dominant as the ideal.

This is an incredibly difficult question to answer for a variety of reasons, most importantly because over the years our once vaunted «beautiful» style of play has become a shadow of it's former self, only to be replaced by a less than stellar «plug and play» mentality where players play out of position and adjustments / substitutions are rarely forthcoming before the 75th minute... if you look at our current players, very few would make sense in the traditional Wengerian system... at present, we don't have the personnel to move the ball quickly from deep - lying position, efficient one touch midfielders that can make the necessary through balls or the disciplined and pacey forwards to stretch defences into wide positions, without the aid of the backs coming up into the final 3rd, so that we can attack the defensive lanes in the same clinical fashion we did years ago... on this current squad, we have only 1 central defender on staf, Mustafi, who seems to have any prowess in the offensive zone or who can even pass two zones through so that we can advance play quickly out of our own end (I have seen some inklings that suggest Holding might have some offensive qualities but too early to tell)... unfortunately Mustafi has a tendency to get himself in trouble when he gets overly aggressive on the ball... from our backs out wide, we've seen pace from the likes of Bellerin and Gibbs and the spirited albeit offensively stunted play of Monreal, but none of these players possess the skill - set required in the offensive zone for the new Wenger scheme which requires deft touches, timely runs to the baseline and consistent crossing, especially when Giroud was playing and his ratio of scored goals per clear chances was relatively low (better last year though)... obviously I like Bellerin's future prospects, as you can't teach pace, but I do worry that he regressed last season, which was obvious to Wenger because there was no way he would have used Ox as the right side wing - back so often knowing that Barcelona could come calling in the off - season, if he thought otherwise... as for our midfielders, not a single one, minus the more confident Xhaka I watched played for the Swiss national team a couple years ago, who truly makes sense under the traditional Wenger model... Ramsey holds onto the ball too long, gives the ball away cheaply far too often and abandons his defensive responsibilities on a regular basis (doesn't score enough recently to justify): that being said, I've always thought he does possess a little something special, unfortunately he thinks so too... Xhaka is a little too slow to ever boss the midfield and he tends to telegraph his one true strength, his long ball play: although I must admit he did get a bit better during some points in the latter part of last season... it always made me wonder why whenever he played with Coq Wenger always seemed to play Francis in a more advanced role on the pitch... as for Coq, he is way too reckless at the wrong times and has exhibited little offensive prowess yet finds himself in and around the box far too often... let's face it Wenger was ready to throw him in the trash heap when injuries forced him to use Francis and then he had the nerve to act like this was all part of a bigger Wenger constructed plan... he like Ramsey, Xhaka and Elneny don't offer the skills necessary to satisfy the quick transitory nature of our old offensive scheme or the stout defensive mindset needed to protect the defensive zone so that our offensive players can remain aggressive in the final third... on the front end, we have Ozil, a player of immense skill but stunted by his physical demeanor that tends to offend, the fact that he's been played out of position far too many times since arriving and that the players in front of him, minus Sanchez, make little to no sense considering what he has to offer (especially Giroud); just think about the quick counter-attack offence in Real or the space and protection he receives in the German National team's midfield, where teams couldn't afford to focus too heavily on one individual... this player was a passing «specialist» long before he arrived in North London, so only an arrogant or ignorant individual would try to reinvent the wheel and / or not surround such a talent with the necessary components... in regards to Ox, Walcott and Welbeck, although they all possess serious talents I see them in large part as headless chickens who are on the injury table too much, lack the necessary first - touch and / or lack the finishing flair to warrant their inclusion in a regular starting eleven; I would say that, of the 3, Ox showed the most upside once we went to a back 3, but even he became a bit too consumed by his pending contract talks before the season ended and that concerned me a bit... if I had to choose one of those 3 players to stay on it would be Ox due to his potential as a plausible alternative to Bellerin in that wing - back position should we continue to use that formation... in Sanchez, we get one of the most committed skill players we've seen on this squad for some years but that could all change soon, if it hasn't already of course... strangely enough, even he doesn't make sense given the constructs of the original Wenger offensive model because he holds onto the ball too long and he will give the ball up a little too often in the offensive zone... a fact that is largely forgotten due to his infectious energy and the fact that the numbers he has achieved seem to justify the means... finally, and in many ways most crucially, Giroud, there is nothing about this team or the offensive system that Wenger has traditionally employed that would even suggest such a player would make sense as a starter... too slow, too inefficient and way too easily dispossessed... once again, I think he has some special skills and, at times, has showed some world - class qualities but he's lack of mobility is an albatross around the necks of our offence... so when you ask who would be our best starting 11, I don't have a clue because of the 5 or 6 players that truly deserve a place in this side, 1 just arrived, 3 aren't under contract beyond 2018 and the other was just sold to Juve... man, this is theraputic because following this team is like an addiction to heroin without the benefits

Lacazette has showed early signs of his pace to get in behind opposition defences, as well as his clinical finishing, as he scored both goals in Arsenal's most recent victory at the Emirates Stadium.

«The identification of a potentially injurious impact or series of impacts via real - time monitoring of head impact exposure in athletes may [not only] facilitate the early recognition and management of brain injury in helmeted sports,» argues Richard M. Greenwald, PhD of the Thayer School of Engineering at Dartmouth College, lead author of an editorial in the March 2012 Clinical Journal of Sports Medicine, [6] but «permit early intervention, potentially in advance of an injury, rather than simply as a management tool postinjury.»

«The identification of a potentially injurious impact or series of impacts via real - time monitoring of head impact exposure in athletes may [not only] facilitate the early recognition and management of brain injury in helmeted sports,» argues Richard M. Greenwald, PhD of the Thayer School of Engineering at Dartmouth College, in an editorial in the March 2012 Clinical Journal of Sports Medicine, [12] but «permit early intervention, potentially in advance of an injury, rather than simply as a management tool postinjury.»

Dr. Ashley Taylor is a licensed clinical psychologist who is endorsed in California as an infant and early childhood mental health specialist.

[204] These methods are intended to reduce practices detrimental to breastfeeding such as early mixed feeding, use of pacifiers, and separation of mother and child in the clinical setting.The BFHI has especially targeted hospitals and birthing centers in the developing world, as these facilities are most at risk to the detrimental effects of reduced breastfeeding rates.

Low family income during the early childhood has been linked to comparatively less secure attachment, 4 higher levels of negative moods and inattention, 5 as well as lower levels of prosocial behaviour in children.2 The link between low family income and young children's problem behaviour has been replicated across several datasets with different outcome measures, including parental reports of externalizing and internalizing behaviours,1 - 3, 7 -9,11-12 teacher reports of preschool behavioural problems, 10 and assessments of children based on clinical diagnostic interviews.7

The PhD course focuses on various aspects of human (donor) milk, with as main study a randomized clinical trial towards the effects of human donor milk in very low birth weight infants (the Early Nutrition Study).

Kelly is a Licensed Certified Social Worker - Clinical (LCSW - C) in Maryland, and works as a Clinical Supervisor to Social Workers in her local Early Intervention Program, the Montgomery County Infants and Toddlers Program (MCITP).

Although some SIDS experts and policy - makers endorse pacifier use recommendations that are similar to those of the AAP, 272,273 concerns about possible deleterious effects of pacifier use have prevented others from making a recommendation for pacifier use as a risk reduction strategy.274 Although several observational studies275, — , 277 have found a correlation between pacifiers and reduced breastfeeding duration, the results of well - designed randomized clinical trials indicated that pacifiers do not seem to cause shortened breastfeeding duration for term and preterm infants.278, 279 The authors of 1 study reported a small deleterious effect of early pacifier introduction (2 — 5 days after birth) on exclusive breastfeeding at 1 month of age and on overall breastfeeding duration (defined as any breastfeeding), but early pacifier use did not adversely affect exclusive breastfeeding duration.

One large clinical trial known as JUPITER reported in 2008 that rosuvastatin (Crestor) lowers the risk of heart attacks and other events by 44 percent in healthy subjects but experts have since raised questions about its methodology in part because the trial was stopped early, which might have created the effect of overestimating the drug's benefits.

Given these auspicious early results, the team is already laying the groundwork for a clinical trial to test RCGD 423 or a similar molecule as a treatment for osteoarthritis or juvenile arthritis.

As explained in DSM - 5, age of onset is now set at 12, rather than an earlier age, to reflect the importance of clinical presentation during childhood for accurate diagnosis, while also acknowledging the difficulties in establishing precise childhood onset retrospectively.

Fiers discovered a key protein on the influenza virus that could serve as a target for a universal vaccine; the drug has shown promise in an early clinical trial.

The identification of the cancer cell of origin has important clinical implications, as it enables doctors to detect malignancies earlier and predict tumor behavior more accurately.

Work on a proof of concept project — code - named Starbrite — began in early 2003 as a collaboration among the Duke Clinical Research Institute (DCRI), Duke Clinic, and CDISC with several technology partners and financial support from several sponsors.

Plus, he points to two clinical studies that have shown that the fever - reducer acetaminophen — commonly known as Tylenol — decreased fever - associated birth defects, and he suggests that doctors and patients consider the drug's use to treat fevers early in pregnancy.

As a researcher, he stresses that it is too early for clinical use.

As Scientific American reported earlier this year, more than half of the current cancer clinical trials do incorporate some form of immunotherapy but still oncologists are often only in the early stages of understanding how to use such treatment on a larger scale.

Among the changes in the American Cancer Society's updated breast cancer screening guideline is that women with an average risk of breast cancer should undergo regular, annual screening mammography beginning at age 45 years, with women having an opportunity to choose to begin annual screening as early as age 40; women 55 years and older should transition to screening every other year (vs annual), but still have the opportunity to continue with annual screening; and routine screening clinical breast examination is no longer recommended, according to an article in the October 20 issue of JAMA.

«These very important early clinical trials could provide hope for patients with all sorts of neurologic problems that involve paralysis such as stroke, brain injury, ALS and even multiple sclerosis.»

HB 661 would permit people with chronic illness to get therapies in early - stage clinical trials — not just terminally ill patients, as the state's current «right - to - try» law does.

Samuel Weiss, PhD, Professor and Director of the HBI, and Research Assistant Professor Artee Luchman, PhD, and colleagues, published their work today in Clinical Cancer Research, which is leading researchers to start a human phase I / II clinical trial as early as SpriClinical Cancer Research, which is leading researchers to start a human phase I / II clinical trial as early as Spriclinical trial as early as Spring 2015.

So now, with late - stage clinical failures piling up, the U.S. Food and Drug Administration (FDA) has set off down a path to adapt those standards as researchers are pushed inexorably into earlier and earlier forms of the disease, ahead of the brain damage inflicted by Alzheimer's.

Clinical trials that charge enrollees to participate are ostensibly aimed at giving patients early access to promising therapies — often in the fields of stem cells or aging reversal — that are too unusual or have too little profit potential to get funding from traditional sources such as companies, foundations, or the National Institutes of Health.

As early as 1978 Alberto Mantovani of Humanitas Clinical Institute and the University of Milan had observed that innate immune cells tend to congregate around some tumorAs early as 1978 Alberto Mantovani of Humanitas Clinical Institute and the University of Milan had observed that innate immune cells tend to congregate around some tumoras 1978 Alberto Mantovani of Humanitas Clinical Institute and the University of Milan had observed that innate immune cells tend to congregate around some tumors.

But Massachusetts's colleges and universities have had an eye on industry for more than a decade, Griesemer says, citing the addition of bioinformatics to computer science programs and clinical trials training to medical school curriculums as early examples.

What is vanishing — if it ever really existed — is a mass of physician - scientists matching an earlier generation's idealized concept of the «triple threat» who could, as a solitary clinical investigator, move effortlessly between bedside and bench, managing a busy clinical practice and a productive research laboratory while devoting significant time to teaching and mentoring.

But the idea of single - subject research didn't really make the leap to medicine of the body until the early 1980s when Gordon Guyatt, a Canadian physician now known as a founder of evidence - based medicine, began working in an interdisciplinary department at McMaster University in Ontario, with psychologists, biostatisticians, ethicists and clinical epidemiologists all working together.

They add: «What is similar between now and then is the human genetic material, our genome, including ancient polymorphisms that were uncovered to predispose the carrier to the development of atherosclerotic cardiovascular disease... however, our ancient ancestors were certainly susceptible to many other conditions, such as infectious diseases, nutritional deprivation, and trauma, which often resulted in death at an early age, before atherosclerotic heart disease had a clinical impact.»

«These splicing signatures could potentially be used as clinical biomarkers to detect blood stem cells that show signs of early aging or leukemia, and to monitor patient responses to treatment,» said Crews.

AKI is largely asymptomatic, lacking warning signs such as pain, shortness of breath or other clinical symptoms, particularly in the early stages when intervention is most beneficial.

In animal studies and early clinical trials, the drug known as Epo (for erythropoietin) appeared to counteract anemia caused by radiation and chemotherapy.

Despite lowering low - density lipoprotein (LDL), known as «bad» cholesterol, while markedly increasing levels of high - density lipoprotein (HDL), or «good» cholesterol, a large clinical trial to investigate the cholesterol drug evacetrapib was discontinued early after a preliminary analysis showed it did not reduce rates of major adverse cardiovascular events, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

«Our present study shows examination of the gene expression profiles at the very early age of initial clinical detection reveals both strong evidence of early biological processes in ASD and abnormal signals with the potential to serve as an early, practical biomarker of risk for the disorder in general pediatric settings.»

Clinical trials of weight loss have been shown to improve participants» mood, but this could be a result of the supportive environment rather than the weight loss itself, as the effects are seen very early on in treatment and are not related to the extent of weight loss.

The research, part of a phase I clinical trial to test the safety of the treatment, was published as a letter to the editor in The New England Journal of Medicine earlier this week and will be in the September issue of Human Gene Therapy.

Limiting clinical investigations to women who are at risk of transmitting a serious mtDNA disease, where the mutation's pathogenicity is undisputed, and the clinical presentation of the disease is predicted to be severe, as characterized by early mortality or substantial impairment of basic functions; and

In early clinical trials of these drugs, we noticed that in some breast cancer patients the tumors didn't just remain the same size — as would be expected with drugs that interfere with cell division — but began to recede, sometimes quite dramatically, said Goel.»

Many clinical symptoms such as abdominal pain, vomiting, nausea and diarrhea were also relieved earlier in the interferon - treated patients.

In my role as a Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Professor of Medicine and Director of Early Phase Clinical Trials Program in the Department of Medicine at Roswell Park Comprehensive Cancer Center, I am developing novel therapies for patients with cancer.

In August 2014, KalVista Pharmaceuticals Ltd. launched an early phase clinical trial of a PKal inhibitor to treat DME, with Jennifer Sun, M.D., Ph.D., of Joslin's Beetham Eye Institute as principal investigator.

In an article published in the Journal of Clinical Oncology (https://doi.org/10.1200/JCO.2017.74.6586), Laenkholm et al report on a study of 2,558 postmenopausal women identified as having HR positive / HER2 - negative, early - stage breast cancer, 1,395 of whom had one to three positive axillary nodes.

Christophe Benoist, M.D., professor of Microbiology and Immunobiology at Harvard Medical School, (who spoke on behalf of Diane Mathis, Ph.D., also a professor in the same department) discussed a molecule called I - BET that, when used as a treatment in animals during pre-diabetes or in the early stages of clinical type 1 diabetes, seemed to slow the progression of the disease.

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

«With no new treatments for Alzheimer's licensed since 2002, we urgently need to capitalise on promising early science to make sure it's progressed as quickly as possible towards clinical testing.

Both hospital units work jointly since 1995 to offer diagnosis and assessment services in families with hereditary cancer, as well as clinical monitoring, prevention, early detection and highly specialised treatments for patients.